ERVFRD-1

Across TCGA pan-cancer cohorts, ERVFRD-1 Mutation is linked to patient survival in 7 of 34 cancer types, making it a survival-associated ERVFRD-1 data layer compared with 26 for mass-spec protein.

The strongest signal is observed in head and neck squamous cell carcinoma (HNSC), where higher ERVFRD-1 Mutation is associated with worse overall survival. In most high-consensus cancer types, elevated ERVFRD-1 expression acts as an unfavorable survival marker.

HNSC, LUSC, and ESCA are the cancer types where ERVFRD-1 Mutation most reproducibly stratifies survival.

Mutation survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
HNSC	OS	Median	All	0.169	0.751	<.001	42	view →
LUSC	OS	Median	All	0.139	0.777	<.001	36	view →
ESCA	OS	Median	II,III,IV	0.117	0.703	<.001	36	view →
LUAD	OS	Median	All	0.246	0.813	<.001	24	view →
BRCA	DFS	Median	III,IV	0.093	0.880	<.001	12	view →
UCEC	OS	Median	IV	0.231	0.592	.036	6	view →
SKCM	DFS	Median	All	0.315	0.740	.014	4	view →

Pink = unfavorable, green = favorable. Showing the 7 strongest of 7 lineages.

ERVFRD-1–HNSC (OS)

Open the HNSC breakdown →